Structured Lipid Compositions with Non-Methylene-Interrupted Fatty Acids
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bioactive fatty acid compositions for treating diseases and conditions are not sufficiently effective, and there is a need for improved compounds and formulations that enhance their therapeutic benefits.
Innovation Solution
Development of structured lipid compositions containing non-methylene-interrupted fatty acids, omega-3 fatty acids, non-beta-oxidizable fatty acids, and conjugated linoleic acids, such as sciadonic acid, eicosapentaenoic acid, docosahexaenoic acid, and tetradecylthioacetic acid, in specific ratios and forms like phospholipids and acylglycerides, for use in dietary supplements and food products.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional bioactive fatty acid compositions are used, then the basic therapeutic function is provided, but the efficacy and therapeutic benefits are not sufficiently effective
Solution Approach 1:
The patent combines multiple types of fatty acids (non-methylene-interrupted fatty acids like sciadonic acid, omega-3 fatty acids, non-beta-oxidizable fatty acids, and conjugated linoleic acids) into a composite lipid composition. This composite structure enhances therapeutic efficacy by leveraging the synergistic effects of different fatty acid types while improving bioavailability through the unique non-methylene-interrupted structure that resists standard metabolic degradation pathways
Solution Approach 2:
The patent modifies the chemical structure parameter of fatty acids by using non-methylene-interrupted configurations (where double bonds are separated by more than one methylene group). This structural parameter change fundamentally alters the metabolic behavior and bioavailability of the fatty acids, allowing them to resist beta-oxidation and maintain therapeutic levels in the body longer than conventional fatty acid compositions
2Stability of the object's composition
If bioactive fatty acids are administered, then therapeutic effects are intended, but the stability and bioavailability are insufficient
Solution Approach 1:
The patent changes the structural parameter of fatty acids from conventional methylene-interrupted configurations to non-methylene-interrupted configurations. This parameter change provides exceptional metabolic stability by preventing standard beta-oxidation pathways, thereby maintaining the integrity and therapeutic potency of the fatty acid composition throughout digestion and metabolism
Data Source
AI summary
Provided herein is technology relating to lipid compositions containing bioactive fatty acids and particularly, but not exclusively, to compositions and methods related to the production and use of structured lipid compositions containing sciadonic and/or pinoleic acid alone or in combination with other bioactive fatty acids including, but not limited to, eicosapentaenoic acid, docosahexaenoic acid, conjugated linoleic acid, and non-β-oxidizable fatty acid analogues such as tetradecylthioacetic acid.